Fulvestrant · Faslodex

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: HR+/HER2- Metastatic Breast Cancer, Breast Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (6)
US
  • Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postm
  • HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy
  • HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib a
  • HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women
Product first approved 2002FDA label
JP
  • Postmenopausal women with hormone receptor-positive metastatic breast cancer that recurred or progressed after prior endocrine therapy (Faslodex)
Product first approved 2011astrazeneca.com
EU
  • Locally advanced or metastatic oestrogen-receptor positive breast cancer in postmenopausal women
Product first approved 2004EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (51)
Breast Cancer
NCT01953588 · Alliance for Clinical Trials in Oncology
2014-02-27 – 2027-04-01 · Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
What this study did
NCT05063786 · Spanish Breast Cancer Research Group
2021-09-14 – 2025-12-23 · Advanced Breast Cancer
What this study did
NCT03447132 · International Cancer Research Group, United Arab Emirates
2017-12-20 – 2021-07-20 · Breast Neoplasm Female
What this study did
NCT00010153 · European Organisation for Research and Treatment of Cancer - EORTC
2000-11 – 2001-10 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07802626 · SWOG Cancer Research Network
2026-10-30 – 2035-10-30 · HR Positive/HER-2 Negative Breast Cancer
What this study did
NCT06757634 · Celcuity Inc
2025-07-24 – 2033-07-30 · Breast Cancer
What this study did
NCT04158362 · UNICANCER
2020-06-11 – 2032-06 · Cancer Metastatic
What this study did
NCT07892274 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2026-11-01 – 2031-12-31 · Metastatic Breast Cancer (MBC), HER2-Positive Breast Cancer, Hormone Receptor-Positive Breast Cancer
What this study did
NCT06982521 · Relay Therapeutics, Inc.
2025-08-26 – 2031-12-31 · PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer
What this study did
NCT02947685 · Alliance Foundation Trials, LLC.
2017-06-21 – 2030-12-31 · HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
What this study did
NCT04646759 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2020-10-14 – 2030-12-14 · Breast Cancer
What this study did
NCT04263298 · Herui Yao
2018-05-01 – 2030-05-01 · Metastatic Breast Cancer
What this study did
NCT07784036 · Chengdu JOYO pharma Co., Ltd.
2026-09-30 – 2029-06-30 · Breast Cancer
What this study did
NCT06447623 · Fudan University
2024-06-11 – 2029-02-01 · Advanced Breast Cancer, HR+/HER2- Breast Cancer
What this study did
NCT03425838 · Borstkanker Onderzoek Groep
2017-11-09 – 2028-12 · Breast Neoplasm Female
What this study did
NCT06612814 · Zhimin Shao
2024-09-01 – 2028-04-30 · Breast Cancer Metastatic
What this study did
NCT02763566 · Eli Lilly and Company
2016-12-05 – 2028-03 · Breast Cancer
What this study did
NCT04975308 · Eli Lilly and Company
2021-10-04 – 2027-08 · Breast Neoplasms, Neoplasm Metastasis
What this study did
NCT06635447 · AstraZeneca
2024-09-26 – 2027-01-10 · Breast Cancer
What this study did
NCT04851613 · Laekna Limited
2022-02-18 – 2026-12-30 · Breast Cancer
What this study did
NCT04337658 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2020-07-01 – 2026-04-30 · HER2-positive Breast Cancer
What this study did
NCT03079011 · UNICANCER
2017-03-22 – 2025-09-22 · Metastatic Breast Cancer
What this study did
NCT02344472 · Prof. Wolfgang Janni
2015-09 – 2025-01-31 · Metastatic Breast Cancer
What this study did
NCT03462251 · iOMEDICO AG
2018-05-24 – 2022-11-30 · Breast Cancer, Hormone Receptor Positive Tumor, HER 2 Negative Breast Cancer
What this study did
NCT00253422 · Institute of Cancer Research, United Kingdom
2004-03-26 – 2022-11-28 · Breast Cancer
What this study did
NCT02028507 · Spanish Breast Cancer Research Group
2014-03-13 – 2021-01-11 · Metastatic Breast Cancer
What this study did
NCT02404051 · Consorzio Oncotech
2015-12 – 2019-01 · Metastatic Breast Cancer, Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Locally Advanced Malignant Neoplasm
What this study did
NCT00075764 · SWOG Cancer Research Network
2004-04 – 2018-10-01 · Breast Cancer
What this study did
NCT02383030 · Consorzio Oncotech
2015-11 – 2017-12 · Metastatic Breast Cancer
What this study did
NCT02394496 · Consorzio Oncotech
2007-11 – 2017-01 · Metastatic Breast Cancer
What this study did
NCT00543127 · Spanish Breast Cancer Research Group
2007-11 – 2016-07 · Breast Cancer
What this study did
NCT00065325 · AstraZeneca
2003-08 – 2014-09 · Locally Advanced Breast Cancer, Metastatic Breast Cancer
What this study did
NCT00545077 · Spanish Breast Cancer Research Group
2007-11-06 – 2014-07-24 · Breast Cancer
What this study did
NCT00390455 · National Cancer Institute (NCI)
2006-09-15 – 2014-07-02 · Estrogen Receptor Positive, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
What this study did
NCT01300351 · AstraZeneca
2011-03 – 2014-03 · Breast Cancer
What this study did
NCT00256698 · AstraZeneca
2004-01 – 2012-02 · Breast Cancer
What this study did
NCT00327769 · AstraZeneca
2005-11 – 2007-09 · Advanced Breast Cancer
What this study did
Phase 2/3 (4)
HR+/HER2- Metastatic Breast Cancer
NCT04753177 · Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary
2021-01-28 – 2024-01-28 · The Neoadjuvant Therapy
What this study did
NCT02692755 · Georgetown University
2016-09 – 2021-03-23 · Hormone Receptor Positive HER-2 Negative Breast Cancer
What this study did
Other / comorbidity
NCT06506955 · Taiho Oncology, Inc.
2024-10-01 – 2027-04-30 · Advanced/Metastatic Cancer
What this study did
Phase 2 (197)
Breast Cancer
NCT02476786 · Washington University School of Medicine
2017-01-17 – 2032-07-31 · Breast Cancer, Cancer of Breast, Breast Neoplasms, Cancer of the Breast
What this study did
NCT04567420 · Criterium, Inc.
2021-02-09 – 2028-12-31 · Breast Cancer
What this study did
NCT07857226 · Hebei Medical University Fourth Hospital
2026-09 – 2028-12 · Breast Cancer
What this study did
NCT07333937 · Xijing Hospital
2025-12-20 – 2028-11-20 · Brest Cancer
What this study did
NCT05328440 · Henan Cancer Hospital
2022-05-20 – 2028-01-01 · Breast Neoplasms
What this study did
NCT03179904 · Mayo Clinic
2017-08-03 – 2026-03-13 · Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, HER2-positive Breast Cancer
What this study did
NCT02760030 · Ohio State University Comprehensive Cancer Center
2017-02-16 – 2025-08-31 · Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
What this study did
NCT05076695 · Fudan University
2021-10-15 – 2024-10-15 · Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer
What this study did
NCT03620643 · Royal Marsden NHS Foundation Trust
2019-05-09 – 2024-08-30 · Lobular Breast Carcinoma, Gastric Cancer, Triple Negative Breast Cancer, CDH1 Gene Mutation
What this study did
NCT04305236 · University of California, Irvine
2020-07-23 – 2022-02-16 · Breast Neoplasm, Hormone Receptor Positive Breast Carcinoma
What this study did
NCT00629616 · UNICANCER
2007-10 – 2018-04 · Breast Cancer
What this study did
NCT00357110 · AstraZeneca
2006-04 – 2008-10 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07716046 · Fudan University
2026-10-01 – 2032-12-31 · Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor-positive Breast Cancer, HR+/HER2+ Breast Cancer
What this study did
NCT07679269 · Novartis Pharmaceuticals
2026-12-15 – 2032-04-20 · PIK3CA-Related Overgrowth Spectrum (PROS), Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation)
What this study did
NCT05524584 · University of California, Irvine
2022-08-31 – 2031-12-31 · Breast Cancer, Metastatic Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
What this study did
NCT07368998 · Hoffmann-La Roche
2026-02-18 – 2031-10-31 · Breast Cancer
What this study did
NCT05933395 · Dartmouth-Hitchcock Medical Center
2024-09-23 – 2031-10 · Advanced Breast Cancer
What this study did
NCT05826964 · University of Miami
2023-06-12 – 2030-11-30 · Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
What this study did
NCT07937605 · Beijing Konruns Pharmaceutical Co., Ltd.
2026-11 – 2030-11 · HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
What this study did
NCT04985266 · Royal Marsden NHS Foundation Trust
2022-03-30 – 2030-09-01 · ER+ Breast Cancer, HER2-negative Breast Cancer
What this study did
NCT05564377 · National Cancer Institute (NCI)
2023-04-07 – 2030-07-01 · Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
What this study did
NCT05226871 · Pfizer
2022-07-07 – 2029-12-31 · Breast Cancer, Head and Neck Cancer
What this study did
NCT04557449 · Pfizer
2020-09-23 – 2029-10-07 · Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
What this study did
NCT07748208 · Hoffmann-La Roche
2026-11-30 – 2029-09-30 · Breast Cancer, Diabetes Type II
What this study did
NCT04606446 · Pfizer
2020-11-16 – 2029-08-27 · Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
What this study did
NCT05467891 · Oana Danciu
2022-09-13 – 2029-08-15 · Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
What this study did
NCT05816655 · Korea University Guro Hospital
2023-05-31 – 2029-06-30 · Metastatic Breast Cancer
What this study did
NCT07426822 · Maryam Lustberg
2026-08-15 – 2029-04 · Metastatic HR+/HER2- Breast Cancer
What this study did
NCT07235618 · Sun Yat-sen University
2026-01-05 – 2028-12-30 · Locally Advanced or Metastatic Breast Cancer
What this study did
NCT06428396 · Merck Sharp & Dohme LLC
2024-11-27 – 2028-12-25 · Metastatic Breast Cancer
What this study did
NCT07227233 · University of California, San Diego
2026-03-31 – 2028-12 · Breast Cancer
What this study did
NCT07619066 · MedSIR
2026-10-04 – 2028-11-28 · Advanced Breast Cancer, Hormone Receptor Positive / HER2-negative Breast Cancer, HER2 Mutation
What this study did
NCT05601440 · Canadian Cancer Trials Group
2023-06-13 – 2028-06-30 · Breast Cancer
What this study did
NCT06179303 · University of Washington
2024-07-22 – 2028-06-01 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma, Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
What this study did
NCT07180160 · Wenjin Yin
2025-09-25 – 2028-03 · Advanced Breast Cancer
What this study did
NCT05392608 · Borstkanker Onderzoek Groep
2022-06-02 – 2028-03 · Neoplasm, Breast, Congenital, Familial and Genetic Disorders
What this study did
NCT05949541 · Fudan University
2023-07-26 – 2028-01 · Breast Cancer, Advanced Breast Cancer
What this study did
NCT05305924 · The Methodist Hospital Research Institute
2021-02-25 – 2027-12-01 · ER-Positive Breast Cancer, HER2-negative Breast Cancer
What this study did
NCT07117630 · Fudan University
2025-09-25 – 2027-12 · Breast Cancer
What this study did
NCT05090358 · Memorial Sloan Kettering Cancer Center
2021-10-08 – 2027-10-08 · Breast Cancer, Breast Cancer Stage IV, Metastatic Breast Cancer
What this study did
NCT03393845 · Nancy Chan, MD
2018-01-29 – 2027-09-01 · Breast Cancer
What this study did
NCT04053322 · UNICANCER
2019-08-26 – 2027-08 · ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer, a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
What this study did
NCT05759572 · Fudan University
2023-03-01 – 2027-07-01 · Breast Cancer Metastatic
What this study did
Phase 1/2 (55)
Breast Cancer
NCT05319873 · Jonsson Comprehensive Cancer Center
2022-04-07 – 2028-04-01 · Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Locally Advanced HER2-Positive Breast Carcinoma, Metastatic HER2-Positive Breast Carcinoma, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT05230810 · Criterium, Inc.
2022-08-25 – 2026-06-30 · HER2-positive Metastatic Breast Cancer
What this study did
NCT02345772 · Western Regional Medical Center
2014-07 – 2015-11 · HER2-positive Breast Cancer, ER-positive Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07558733 · Faeth Therapeutics
2026-04-22 – 2033-05 · HR+ HER2- Breast Cancer
What this study did
NCT07811232 · Advenchen Pharmaceuticals, LLC.
2026-09-01 – 2031-09-01 · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
What this study did
NCT07570966 · Novartis Pharmaceuticals
2026-06-30 – 2031-08-01 · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer (mCRPC)
What this study did
NCT07288359 · Novartis Pharmaceuticals
2025-12-29 – 2031-05-09 · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
What this study did
NCT03424005 · Hoffmann-La Roche
2018-03-30 – 2030-09-30 · Metastatic Breast Cancer
What this study did
NCT06998407 · Avenzo Therapeutics, Inc.
2025-08-20 – 2030-08 · HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer
What this study did
NCT05768139 · Eli Lilly and Company
2023-04-17 – 2030-07 · Breast Cancer, Solid Tumors, Adult
What this study did
NCT05867251 · Avenzo Therapeutics, Inc.
2023-08-30 – 2030-01-31 · Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, TNBC - Triple-Negative Breast Cancer
What this study did
NCT06788197 · Henan Cancer Hospital
2025-03 – 2029-03-31 · Breast Cancer, Locally Advanced or Metastatic Breast Cancer
What this study did
NCT07861932 · KymaThera, Inc.
2026-10-14 – 2029-03 · Breast Neoplasms, Solid Tumors, PIK3CA Gene Mutation
What this study did
NCT07109726 · Terremoto Biosciences Inc.
2025-09-23 – 2029-02-28 · Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Solid Tumor, Cervical Cancer
What this study did
NCT05608252 · Adrienne G. Waks
2023-02-23 – 2028-12-31 · Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
What this study did
NCT07287917 · Aminex Therapeutics, Inc.
2026-01-26 – 2028-12-29 · Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
What this study did
NCT07389733 · Shandong Suncadia Medicine Co., Ltd.
2026-03-27 – 2028-12 · Advanced Unresectable or Metastatic Breast Cancer of Adults
What this study did
NCT06726148 · Novartis Pharmaceuticals
2025-04-03 – 2028-09-25 · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
What this study did
NCT06555068 · Jiangsu HengRui Medicine Co., Ltd.
2024-08-12 – 2028-08 · Advanced Unresectable or Metastatic Breast Cancer, Advanced Solid Tumors
What this study did
NCT06993844 · Ensem Therapeutics
2025-06-10 – 2027-12-30 · Advanced Solid Tumors, Advanced Breast Cancer
What this study did
NCT06110793 · Memorial Sloan Kettering Cancer Center
2023-12-29 – 2027-11 · Metastatic Breast Cancer
What this study did
NCT05986071 · Institut Paoli-Calmettes
2024-05-01 – 2027-10-15 · Breast Cancer
What this study did
NCT06202261 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2023-04-13 – 2027-10 · Metastatic Breast Cancer, Recurrent Breast Cancer, Advanced Malignancies
What this study did
NCT05735080 · Incyclix Bio
2023-03-28 – 2027-09 · Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Ovarian Cancer, CCNE1 Amplification, Solid Tumor, Advanced Cancer, Metastatic Cancer
What this study did
NCT04115306 · Phoenix Molecular Designs
2019-11-14 – 2026-12 · Metastatic Breast Cancer
What this study did
NCT05191004 · Nuvation Bio Inc.
2022-09 – 2026-09 · Advanced Breast Cancer, Metastatic Breast Cancer, Breast Cancer, Breast Carcinoma, Cancer of the Breast, Cancer of Breast, Malignant Tumor of Breast, Breast Tumor
What this study did
NCT05251714 · Treadwell Therapeutics, Inc
2022-05-27 – 2026-08 · Advanced Solid Tumor, Breast Cancer
What this study did
NCT04539496 · Sihuan Pharmaceutical Holdings Group Ltd.
2018-05-22 – 2025-12-31 · Metastasis Solid Tumors, Advanced Breast Cancer
What this study did
NCT01992952 · Velindre NHS Trust
2014-05-07 – 2025-12-31 · Estrogen Receptor Positive Breast Cancer
What this study did
NCT03772353 · Fudan University
2019-05-12 – 2025-12-10 · Breast Cancer
What this study did
NCT04282031 · Beta Pharma (Suzhou) Co., Ltd.
2020-06-15 – 2025-06-30 · Advanced Solid Tumor, HR+/HER2- Breast Cancer
What this study did
NCT05792410 · Jiangsu HengRui Medicine Co., Ltd.
2023-04 – 2025-02-27 · HER2 Low Advanced or Metastatic Breast Cancer
What this study did
NCT05574881 · Fudan University
2022-09-01 – 2025-01-01 · Breast Cancer
What this study did
NCT05176080 · Henan Cancer Hospital
2021-12-08 – 2024-07-03 · Metastatic Breast Cancer
What this study did
NCT05054374 · Memorial Sloan Kettering Cancer Center
2021-09-14 – 2023-10-26 · Breast Cancer, Breast Cancer Stage IV, HER2-negative Breast Cancer, Solid Carcinoma, MEK1 Gene Mutation, MEK2 Gene Mutation, Metastatic Breast Cancer
What this study did
NCT02983071 · G1 Therapeutics, Inc.
2017-01 – 2023-10 · Carcinoma, Ductal, Breast, Breast Cancer, Breast Neoplasm
What this study did
NCT03481998 · Jiangsu HengRui Medicine Co., Ltd.
2018-03-22 – 2022-07-30 · Advanced Breast Cancer
What this study did
NCT03803761 · National Cancer Institute (NCI)
2019-02-13 – 2022-02-19 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT04355520 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2020-07 – 2021-09 · HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
What this study did
NCT03344536 · Memorial Sloan Kettering Cancer Center
2017-11-10 – 2021-08-12 · Breast Cancer
What this study did
NCT00903006 · M.D. Anderson Cancer Center
2009-11 – 2013-05 · Breast Cancer
What this study did
Other / comorbidity
NCT07767474 · Antares Therapeutics, Inc
2026-08-31 – 2030-01-31 · Advanced Solid Tumors
What this study did
NCT07944092 · Frontier Medicines Corporation
2026-12 – 2030-01 · Locally Advanced Solid Tumor
What this study did
NCT05394103 · Qurient Co., Ltd.
2022-08-30 – 2029-08-31 · Advanced Cancer, Metastatic Cancer
What this study did
NCT06736704 · Pikavation Therapeutics, Inc.
2025-02-20 – 2027-06 · Advanced Solid Tumors
What this study did
NCT06208410 · Risen (Suzhou) Pharma Tech Co., Ltd.
2024-01-11 – 2027-02-26 · Advanced Solid Tumors
What this study did
NCT04092673 · Effector Therapeutics
2019-10-25 – 2025-03-31 · Solid Tumor, Adult
What this study did
NCT03363893 · Carrick Therapeutics Limited
2017-11-14 – 2022-12-15 · Advanced Solid Malignancies
What this study did
Phase 1 (94)
HR+/HER2- Metastatic Breast Cancer
NCT07604571 · Novartis Pharmaceuticals
2026-05-28 – 2032-06-08 · Advanced HR+/HER2- Breast Cancer
What this study did
NCT05870579 · Novartis Pharmaceuticals
2023-11-13 – 2032-05-27 · Breast Cancer
What this study did
NCT07897721 · Pfizer
2026-11-09 – 2032-03-21 · Advanced Breast Cancer, Advanced or Metastatic Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Metastatic Colorectal Adenocarcinoma
What this study did
NCT07318805 · Pfizer
2025-12-23 – 2030-04-14 · Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Triple Negative Breast Cancer
What this study did
NCT06120283 · BeOne Medicines
2023-12-01 – 2029-12 · Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
What this study did
NCT07905001 · Prelude Therapeutics Incorporated
2026-11-16 – 2029-10-31 · Breast Cancer, Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, HR-positive Breast Cancer, HR+/HER2- Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer
What this study did
NCT07038369 · Atavistik Bio, Inc
2025-07-29 – 2029-01-31 · Advanced Solid Tumors, Breast Cancer, Breast Carcinoma, Breast Neoplasms, ER Positive Breast Cancer, Cervical Cancers, Cervical Neoplasms, Cervical Carcinoma, Triple Negative Breast Cancer, Gynecologic Cancers, Gynecologic Neoplasm, Endometrial Cancer, Endometrial Neoplasm, Endometrial Carcinoma (EC), Fallopian Cancer, Ovarian Carcinoma, Ovarian Cancer, Ovarian Neoplasms, Prostate Cancers, Prostate Carcinoma, Solid Tumors, Neoplasms, Neoplasms by Site, Breast Diseases, Uterine Neoplasms, Genital Neoplasms, Female, Urogenital Neoplasms
What this study did
NCT06997029 · Bristol-Myers Squibb
2025-08-01 – 2028-12-14 · Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer
What this study did
NCT06625775 · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
2024-10-29 – 2028-11 · Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors, HER2-positive Metastatic Breast Cancer, KRAS Mutant Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Colorectal Cancer, Advanced Lung Cancer, HR-positive, HER2-negative Advanced Breast Cancer, HER2-positive Advanced Breast Cancer
What this study did
NCT06941142 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2025-04-30 – 2028-06 · Advanced Breast Cancer
What this study did
NCT05905341 · Pfizer
2024-01-15 – 2028-04-13 · Breast Cancer, Ovarian Cancer, Liposarcoma, Non-small Cell Lung Cancer (NSCLC), Endometrial, Solid Tumors
What this study did
NCT04316169 · Medical College of Wisconsin
2021-10-21 – 2028-01 · Solid Tumor, Advanced Breast Cancer
What this study did
NCT06515470 · Biotheryx, Inc.
2024-07-03 – 2027-12-31 · Breast Cancer
What this study did
NCT07557004 · Nanjing Sanhome Pharmaceutical, Co., Ltd.
2025-09-30 – 2027-12-31 · HR+ / HER2- Advanced Breast Cancer
What this study did
NCT07029399 · NiKang Therapeutics, Inc.
2025-03-25 – 2027-12-31 · HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
What this study did
NCT07923214 · Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.
2024-07-02 – 2027-12 · Advanced Solid Tumors, Breast Cancer, Ovarian Cancer, Gastric Cancer, Other Solid Tumors
What this study did
NCT05683418 · Totus Medicines
2023-02-15 – 2027-12 · HR+/HER2-negative Breast Cancer
What this study did
NCT06784193 · Olema Pharmaceuticals, Inc.
2024-12-16 – 2027-08-30 · Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer, Fulvestrant, Palazestrant
What this study did
NCT06257264 · BeiGene
2024-03-11 – 2027-08-27 · Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced Solid Tumor, Endometrial Cancer, Prostate Cancer, TNBC - Triple-Negative Breast Cancer, GastroEsophageal Cancer, Bladder Cancer
What this study did
NCT06239467 · OnKure, Inc.
2024-02-26 – 2027-08-01 · Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation
What this study did
NCT03959891 · Massachusetts General Hospital
2019-05-30 – 2027-08 · Breast Cancer
What this study did
NCT03939897 · National Cancer Institute (NCI)
2020-06-17 – 2027-07-31 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Recurrent Breast Carcinoma
What this study did
NCT06756932 · BeOne Medicines
2025-02-04 – 2027-07-30 · Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
What this study did
NCT04556773 · AstraZeneca
2020-12-17 – 2027-06-01 · Metastatic Breast Cancer
What this study did
NCT05216432 · Relay Therapeutics, Inc.
2021-12-08 – 2027-04-30 · PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor
What this study did
NCT05307705 · Eli Lilly and Company
2022-05-11 – 2026-12 · Breast Cancer
What this study did
NCT07163481 · Hunan Cancer Hospital
2025-10 – 2026-12 · Stage IV (Metastatic) Breast Cancer
What this study did
NCT02057133 · Eli Lilly and Company
2014-03-10 – 2026-12 · Breast Neoplasms
What this study did
NCT07408089 · Boundless Bio, Inc.
2026-02-25 – 2026-07-28 · Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer
What this study did
NCT05238831 · OHSU Knight Cancer Institute
2023-01-30 – 2026-05-31 · Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT06253195 · BeOne Medicines
2024-04-01 – 2026-04-23 · Advanced Solid Tumor, Metastatic Solid Tumor, Hormone-receptor-positive Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer
What this study did
NCT01597388 · AstraZeneca
2012-05-08 – 2026-01-13 · Advanced Metastatic Breast Cancer
What this study did
NCT05504213 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2022-01-12 – 2025-12-31 · Breast Cancer
What this study did
NCT03685331 · Abramson Cancer Center at Penn Medicine
2020-10-15 – 2025-12-01 · Metastatic Breast Cancer, Locally Advanced Breast Cancer, Advanced Breast Cancer, BRCA2 Mutation, BRCA1 Mutation
What this study did
NCT05252416 · Blueprint Medicines Corporation
2022-04-07 – 2025-07-04 · Advanced Solid Tumors, HR+ Breast Cancer, CCNE1 Amplification, HER2-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Gastric Cancer, Esophageal Adenocarcinoma, Carcinosarcoma
What this study did
NCT06172322 · Nanjing Chia-tai Tianqing Pharmaceutical
2023-12-28 – 2025-07 · HR Positive/HER-2 Negative Breast Cancer
What this study did
NCT04498520 · Pamela Munster
2021-03-31 – 2025-06-30 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Endometrioid Adenocarcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Breast Carcinoma, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8
What this study did
NCT02792465 · University Health Network, Toronto
2016-11-11 – 2025-06-12 · Advanced Solid Cancers, Breast Cancer
What this study did
NCT05759949 · Relay Therapeutics, Inc.
2023-03-29 – 2025-04-11 · PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Hormone Receptor Positive Tumor
What this study did
NCT03854903 · Georgetown University
2019-04-01 – 2025-01-09 · Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor Positive Breast Cancer
What this study did
NCT05384119 · Tvardi Therapeutics, Incorporated
2023-01-09 – 2024-05-06 · Breast Cancer
What this study did
NCT04726332 · Exelixis
2021-02-10 – 2024-05-02 · Neoplasm Malignant, Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
What this study did
NCT02913430 · Shannon Puhalla
2018-04-24 – 2024-04-30 · Metastatic Breast Cancer
What this study did
NCT03238196 · Vanderbilt-Ingram Cancer Center
2017-08-18 – 2024-03-20 · Metastatic Breast Cancer
What this study did
NCT03767335 · Menarini Group
2018-11-13 – 2024-02-23 · Advanced or Metastatic Breast Cancer
What this study did
Phase 4 (9)
HR+/HER2- Metastatic Breast Cancer
NCT05161195 · Novartis Pharmaceuticals
2022-07-07 – 2030-08-14 · Metastatic Breast Cancer
What this study did
NCT05362760 · Prof. Wolfgang Janni
2022-04-27 – 2029-04 · Hormone Receptor-positive Metastatic Breast Cancer, HER2-negative Metastatic Breast Cancer
What this study did
NCT04707196 · Eli Lilly and Company
2021-02-22 – 2023-01-09 · Breast Neoplasms, Neoplasm Metastasis
What this study did
NCT05191914 · Liaoning Cancer Hospital & Institute
2022-02-07 – 2022-12-30 · Breast Cancer
What this study did
NCT03220178 · Palleos Healthcare GmbH
2017-07-24 – 2021-12-07 · Breast Neoplasm
What this study did
NCT03591549 · Assiut University
2018-08-01 – 2021-10-01 · Metastatic Breast Cancer
What this study did
NCT02447328 · AstraZeneca
2015-05-29 – 2020-09-16 · Locally Advanced or, Metastatic Breast Cancer
What this study did
NCT04031885 · Eli Lilly and Company
2019-08-14 – 2020-08-11 · Metastatic Breast Cancer
What this study did
Early phase / not applicable (6)
Breast Cancer
NCT00126464 · Cedars-Sinai Medical Center
started 2004-11 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06856200 · Fudan University
2025-02-28 – 2026-06 · Advanced HR - Positive, HER2 - Negative Breast Cancer, Resistant to (Neo)Adjuvant Endocrine Therapy
What this study did
NCT05047848 · Liaoning Cancer Hospital & Institute
2021-08-18 – 2023-09-18 · Advanced Breast Cancer
What this study did
NCT03768479 · First Affiliated Hospital Xi'an Jiaotong University
2017-03-05 – 2019-03 · Estrogen Receptor-positive Breast Cancer, Fulvestrant
What this study did
NCT03507088 · Zhimin Shao
2015-09-01 – 2018-07-01 · Metastatic Breast Cancer
What this study did
NCT00816582 · British Columbia Cancer Agency
2010-11-30 – 2018-07 · Breast Cancer
What this study did
Used as active comparator (29)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (11)
HR+/HER2- Metastatic Breast Cancer
NCT07354022 · Shandong Suncadia Medicine Co., Ltd.
2026-05-05 – 2031-12 · Locally Advanced or Metastatic Breast Cancer
What this study did
NCT04862663 · AstraZeneca
2021-05-10 – 2029-08-14 · Locally Advanced (Inoperable) or Metastatic Breast Cancer
What this study did
NCT06065748 · Hoffmann-La Roche
2023-12-11 – 2029-02-12 · Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
What this study did
NCT06954961 · InventisBio Co., Ltd
2022-09-15 – 2028-12-31 · Breast Cancer
What this study did
NCT06680921 · Jiangsu Simcere Pharmaceutical Co., Ltd.
2024-11-14 – 2028-08-31 · Locally Advanced or Metastatic Breast Cancer
What this study did
NCT05654623 · Pfizer
2023-03-03 – 2028-05-15 · Advanced Breast Cancer
What this study did
NCT06016738 · Olema Pharmaceuticals, Inc.
2023-11-16 – 2028-02-29 · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
What this study did
NCT07024173 · Shandong Suncadia Medicine Co., Ltd.
2025-07-23 – 2027-12 · Locally Advanced Breast Cancer, Metastatic Breast Cancer
What this study did
NCT05306340 · Genentech, Inc.
2022-08-03 – 2027-06-15 · Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
What this study did
NCT05065411 · Veru Inc.
2022-04-11 – 2024-01-09 · Metastatic Breast Cancer
What this study did
Phase 2 (12)
Breast Cancer
NCT05472792 · UNC Lineberger Comprehensive Cancer Center
2022-05-17 – 2032-04-15 · Breast Cancer, Quality of Life
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07729046 · University of California, San Diego
2027-07 – 2035-06 · Metastatic Invasive Breast Cancer, Resistant Breast Cancer, ER+, HER2-, Metastatic Breast Cancer
What this study did
NCT04576455 · Hoffmann-La Roche
2020-11-27 – 2027-08-25 · Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
What this study did
NCT05181033 · National University Hospital, Singapore
2021-12-27 – 2027-08 · Breast Cancer
What this study did
NCT04214288 · AstraZeneca
2020-04-22 – 2027-06-16 · Advanced ER-Positive HER2-Negative Breast Cancer
What this study did
NCT06339281 · Li Huiping
2024-05-01 – 2026-12 · Advanced Breast Cancer
What this study did
NCT03781063 · Sermonix Pharmaceuticals Inc.
2019-09-20 – 2025-05-08 · Locally Advanced or Metastatic Breast Cancer
What this study did
NCT04059484 · Sanofi
2019-10-22 – 2025-01-02 · Breast Cancer Metastatic
What this study did
NCT05101564 · Jennifer Lee Caswell-Jin
2023-03-20 – 2024-06-03 · Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer
What this study did
NCT03024580 · Instituto Nacional de Cancer, Brazil
2017-03-06 – 2020-09 · Breast Neoplasm
What this study did
NCT02569801 · Genentech, Inc.
2015-12-04 – 2020-02-28 · Breast Cancer
What this study did
NCT00728949 · Eli Lilly and Company
2008-08 – 2015-02 · Metastatic Breast Cancer
What this study did
Phase 1/2 (3)
HR+/HER2- Metastatic Breast Cancer
NCT02983604 · Gilead Sciences
2017-01-10 – 2018-07-19 · Advanced Estrogen Receptor Positive HER2- Breast Cancer
What this study did
NCT01202591 · AstraZeneca
2010-12 – 2014-10 · FGFR Inhibition, Pharmacokinetics, Biomarkers, ER+ Breast Cancer
What this study did
Phase 1 (3)
HR+/HER2- Metastatic Breast Cancer
NCT03236974 · AstraZeneca
2017-10-05 – 2019-02-12 · Postmenopausal Women With ER+ HER2- Primary Breast Cancer
What this study did
Other / comorbidity
NCT07366632 · Shanghai Best-Link Bioscience, LLC
2026-01-26 – 2026-12-21 · Postmenopausal Women
What this study did
NCT03324061 · Eagle Pharmaceuticals, Inc.
2017-11-30 – 2018-07-12 · Pharmacokinetics
What this study did
Studied as part of a combination product (4)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 2 (1)
HR+/HER2- Metastatic Breast Cancer
NCT04553133 · Pfizer
2020-09-16 – 2026-12-31 · Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
What this study did
Phase 1/2 (3)
HR+/HER2- Metastatic Breast Cancer
NCT07235176 · Qilu Pharmaceutical Co., Ltd.
2026-01-16 – 2031-12-30 · Advanced ER+/HER2- Breast Cancer
What this study did
NCT05573126 · Ellipses Pharma
2023-01-11 – 2028-02 · Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
What this study did
NCT05262400 · Pfizer
2022-03-14 – 2027-02-26 · Breast Cancer, Solid Tumors
What this study did
Appears in other studies (44)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (22)
HR+/HER2- Metastatic Breast Cancer
NCT07174336 · Eli Lilly and Company
2025-12-22 – 2033-05 · Breast Neoplasms, Neoplasm Metastasis
What this study did
NCT07393321 · Nanjing Chia-tai Tianqing Pharmaceutical
2026-02-10 – 2031-08-31 · HR Positive/HER2 Negative Advanced or Metastatic Breast Cancer
What this study did
NCT05077449 · Xuanzhu Biopharmaceutical Co., Ltd.
2021-11-16 – 2029-11 · Advanced Breast Cancer
What this study did
NCT02107703 · Eli Lilly and Company
2014-07-22 – 2027-12 · Breast Neoplasms
What this study did
NCT06929325 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2025-04 – 2027-12 · HR+/HER2- Advanced/Metastatic Breast Cancer
What this study did
NCT05169567 · Eli Lilly and Company
2022-03-11 – 2027-12 · Breast Neoplasm, Neoplasm Metastasis
What this study did
NCT04650581 · Canadian Cancer Trials Group
2021-01-27 – 2026-12-31 · Breast Cancer
What this study did
NCT04305496 · AstraZeneca
2020-04-16 – 2026-06-22 · Locally Advanced (Inoperable) or Metastatic Breast Cancer
What this study did
NCT05207709 · SOLTI Breast Cancer Research Group
2022-03-28 – 2026-03-26 · Metastatic Breast Cancer
What this study did
NCT05433480 · Betta Pharmaceuticals Co., Ltd.
2022-05-25 – 2025-07-31 · Breast Cancer
What this study did
NCT05054751 · Genor Biopharma Co., Ltd.
2021-09-10 – 2024-03-30 · Locally Advanced or Metastatic Breast Cancer
What this study did
NCT02422615 · Novartis Pharmaceuticals
2015-06-09 – 2023-01-11 · Advanced Breast Cancer
What this study did
NCT03927456 · Jiangsu HengRui Medicine Co., Ltd.
2019-06-13 – 2022-12-30 · Advanced Breast Cancer
What this study did
NCT01942135 · Pfizer
2013-09-26 – 2022-09-28 · Metastatic Breast Cancer
What this study did
NCT02137837 · SWOG Cancer Research Network
2014-05 – 2019-12-31 · Breast Cancer
What this study did
NCT01633060 · Novartis Pharmaceuticals
2012-10-03 – 2017-09-21 · Metastatic Breast Cancer
What this study did
Phase 2/3 (1)
Phase 2 (20)
Breast Cancer
NCT07179939 · Fudan University
2025-09-10 – 2031-12-30 · HER2-positive Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT02955394 · University of Colorado, Denver
2017-09-21 – 2027-02 · Breast Cancer
What this study did
NCT04544189 · Novartis Pharmaceuticals
2021-01-20 – 2027-01-29 · Breast Neoplasms
What this study did
NCT03147287 · Dana-Farber Cancer Institute
2017-09-05 – 2026-12-30 · Metastatic Breast Cancer
What this study did
NCT06607757 · GBG Forschungs GmbH
2024-12-04 – 2026-08-31 · CCCA Assessed by Ki67 Drop Below <2.7% From Baseline
What this study did
NCT05554354 · National Cancer Institute (NCI)
2024-09-13 – 2025-04-04 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
What this study did
NCT05085002 · EQRx, Inc.
2021-12-21 – 2023-11-29 · Advanced Breast Cancer
What this study did
NCT02632045 · Melissa K Accordino
2016-03 – 2022-01-04 · Metastatic Breast Cancer, Breast Carcinoma
What this study did
NCT02216786 · Queen Mary University of London
2014-01-16 – 2021-12-31 · Estrogen Receptor Positive Breast Cancer
What this study did
NCT03584009 · Hoffmann-La Roche
2018-09-06 – 2021-05-06 · Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
What this study did
NCT02530411 · Velindre NHS Trust
2015-04 – 2020-12 · Neoplasms
What this study did
NCT02756364 · Calithera Biosciences, Inc
2016-07-28 – 2019-11-25 · Breast Neoplasms
What this study did
NCT03241810 · Elevation Oncology
2017-08-15 – 2018-11-30 · Metastatic Breast Cancer
What this study did
NCT00451555 · Eli Lilly and Company
2007-04-11 – 2018-10-18 · Breast Cancer
What this study did
NCT02115594 · Syndax Pharmaceuticals
2014-04 – 2016-06 · Breast Cancer
What this study did
NCT00454805 · AstraZeneca
2007-03 – 2016-04 · Advanced Breast Cancer
What this study did
NCT01528345 · Novartis Pharmaceuticals
2012-04 – 2015-04 · Metastatic Breast Cancer
What this study did
Phase 4 (1)

Competitive landscape

This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for HR+/HER2- Metastatic Breast Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Fulvestrant (Faslodex): this drugApprovedSmall moleculeEstrogen receptorPartial signal
NCT01602380: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59)
NCT00099437: Progression-free survival: fulvestrant 500 mg (n=362) vs 250 mg (n=374), HR 0.80 (95% CI 0.68 to 0.94), P = .006; CT.gov median time to progression 6.5 vs 5.5 months (Di Leo et al., J Clin Oncol 2010).
Abemaciclib (Verzenio)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02107703: Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4)
NCT02102490: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)): Abemaciclib 19.7% (95% CI 13.3 to 27.5)
Alpelisib (BYL719)ApprovedSmall moleculePI3K-alphaReliable signal
NCT02437318: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36)
AnastrozoleApprovedSmall moleculeAromatasenot yet graded
NCT00291759: Recurrence-free survival, 2yr tamoxifen then 3yr anastrozole vs 5yr tamoxifen: HR 0.80 (95% CI 0.63-1.01), P=.06 (not statistically significant) missed phase 3 result · pivotal pending
NCT00300508: At a median follow-up of 62.3 months, women who received anastrozole (n=387) had a statistically significantly reduced risk of recurrence (locoregional recurrence, contralateral breast cancer or distant metastasis) versus women who received no further treatment (n=469): hazard ratio 0.62 (95% CI 0.40-0.96), P=.031. phase 3 result · pivotal pending
Camizestrant (Etcamah)ApprovedSmall moleculeEstrogen receptorReliable signal
NCT04964934: SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001
NCT04588298: Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81)
Capecitabine
ApprovedUS marketing discontinued
Small moleculeFluoropyrimidine (antimetabolite)not yet gradedNo reviewed efficacy summary in this indication
CapivasertibApprovedSmall moleculeAKT (inhibitor)Reliable signal
NCT04305496: Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.): Capivasertib + Fulvestrant (Global + China Cohort) 7.2 Months (95% CI 5.5 to 7.4) vs Placebo + Fulvestrant (Global + China Cohort) 3.6 Months (95% CI 2.8 to 3.7)
NCT01625286: Progression-free survival, Part B (randomized vs placebo + paclitaxel): median 10.9 months (95% CI 8.3 to 12.4) with capivasertib vs 8.4 months (95% CI 8.2 to 10.8) with placebo; HR 0.80 (95% CI 0.60 to 1.06), p=0.308 (CT.gov posted results). missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT05104866: Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)Partial signal
NCT00002662: ORR (the registered first objective) 32% vs 25% (P=.10); OS 15.4 vs 12.7 months (P=.03) and TTP 5.7 vs 3.6 months (P<.0001) favored docetaxel. missed
ElacestrantApprovedSmall moleculeEstrogen receptorPartial signal
NCT03778931: Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14)
Eribulin MesylateApprovedSmall moleculeTubulin / microtubulesPartial signal
NCT02225470: Progression-Free Survival, eribulin vs vinorelbine (independent tumor assessment): HR 0.80 (95% CI 0.65-0.98, P=0.036) in favor of eribulin; median PFS 2.8 months in both arms
NCT00337103: Co-primary endpoints, eribulin (n=554) vs capecitabine (n=548): overall survival median 15.9 vs 14.5 months, HR 0.88 (95% CI 0.77 to 1.00), P = .056; progression-free survival median 4.1 vs 4.2 months, HR 1.08 (95% CI 0.93 to 1.25), P = .30 (Kaufman et al., J Clin Oncol 2015). missed
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Weak signal
NCT02511639: Median progression-free survival: 9.9 months (everolimus + aromatase inhibitor) vs 7.2 months (aromatase inhibitor alone); HR 0.764 (95% CI 0.501-1.164)
NCT00863655: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. (date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months): Everolimus + Exemestane 6.93 months (95% CI 6.44 to 8.05) vs Placebo + Exemestane 2.83 months (95% CI 2.76 to 4.14)
ExemestaneApprovedSmall moleculeAromatasePartial signal
NCT00002777: Objective response rate: 46% exemestane vs 31% tamoxifen (odds ratio 1.85, 95% CI 1.21-2.82, P=.005). Median progression-free survival (the trial's primary endpoint): 9.9 months exemestane vs 5.8 months tamoxifen; long-term log-rank P=.121 (not statistically significant). missed
Gedatolisib (Revtorpyk)ApprovedSmall moleculePI3K (class I isoforms) and mTORC1/mTORC2Partial signal
NCT05501886: VIKTORIA-1 (NCT05501886), PIK3CA wild-type cohort, primary endpoint PFS: gedatolisib+fulvestrant+palbociclib (triplet) median PFS 9.3 months vs fulvestrant alone 2.0 months, HR 0.24 (95% CI 0.17-0.35), p<0.0001; gedatolisib+fulvestrant (doublet) median PFS 7.4 months, HR 0.33 (95% CI 0.24-0.48), p<0.0001.
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Weak signal
NCT00128310: Median progression-free survival: 6.0 months (gemcitabine + vinorelbine) vs 4.0 months (vinorelbine alone); hazard ratio 0.66 (p=0.0028). Overall survival not significantly different (15.9 vs 16.4 months, p=0.8046)
NCT00006459: Eli Lilly's pivotal phase III global registration trial of gemcitabine + paclitaxel vs paclitaxel alone in anthracycline-pretreated advanced breast cancer, matching this listing's title/sponsor. Primary endpoint (overall survival): 18.6 vs 15.8 months, HR 0.78 (95% CI 0.64-0.96), p=0.0187, favoring the gemcitabine combination.
GoserelinApprovedPeptideGnRH receptor (agonist)not yet gradedNo reviewed efficacy summary in this indication
Imlunestrant (Inluriyo)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT04975308: Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001
Inavolisib (Itovebi)ApprovedSmall moleculePI3K-alphaReliable signal
NCT04191499: Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3)
IxabepiloneApprovedSmall moleculeMicrotubules (tubulin)Partial signalFeatured results are non-efficacy only in this race
LetrozoleApprovedSmall moleculeAromatasenot yet graded
NCT00003140: Estimated 4-year disease-free survival: letrozole 93% vs placebo 87% (75 vs 132 recurrences/new cancers out of 5187 enrolled); P<=0.001 phase 3 result · pivotal pending
NCT00004205: Disease-free survival (primary endpoint), letrozole vs tamoxifen: 5-year DFS 84.0% vs 81.4%; HR 0.81 (95% CI 0.70-0.93), P=0.003, at median follow-up 25.8 months (351 vs 428 events; N=8010). phase 3 result · pivotal pending
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00785291: Progression Free Survival (Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years)): Arm B (Nab-paclitaxel) 9.3 months (95% CI 8.15 to 10.45) vs Arm A (Paclitaxel) 10.97 months (95% CI 9.79 to 12.42) vs Arm C (Ixabepilone) 7.36 months (95% CI 6.21 to 8.18) missed
OlaparibApprovedSmall moleculePARPPartial signal
NCT02000622: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3)
NCT03286842: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants (At every visit until the earliest of disease progression, death or end of study (up to 3 years)): Olaparib gBRCAm Cohort 8.18 months (95% CI 6.97 to 9.17)
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02297438: Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6)
NCT01740427: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)): Palbociclib Plus Letrozole 24.8 Months vs Placebo Plus Letrozole 14.5 Months (95% CI 12.9 to 17.1)
RibociclibApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02422615: Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3)
NCT02278120: Progression Free Survival (PFS) by Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 29 months): Ribociclib + NSAI/Tamoxifen + Goserelin 23.8 Months vs Placebo + NSAI/Tamoxifen+ Goserelin 13 Months (95% CI 11 to 16.4)
Sacituzumab GovitecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT03901339: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4)
TalazoparibApprovedSmall moleculePARPPartial signal
NCT01945775: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7)
Tamoxifen (Soltamox)ApprovedSmall moleculeEstrogen receptornot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT04494425: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9)
NCT03734029: Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1)
Vepdegestrant (Veppanu)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT05654623: PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025).
NCT04072952: Clinical benefit rate 38% (total n=71), the trial's primary endpoint (VERITAC expansion); CBR 51.2% in ESR1-mutant patients (n=41)
AfuresertibPhase 3Small moleculeAKT (inhibitor)Partial signal
NCT04851613: Primary endpoint, progression-free survival: median 7.6 months with afuresertib plus fulvestrant vs 2.0 months with placebo plus fulvestrant (sponsor topline, 2026-04-15).
Anbenitamab RepodatecanPhase 3Antibody–drug conjugateHER2 (biparatopic — extracellular domains II and IV)not yet gradedNo reviewed efficacy summary in this indication
AtirmociclibPhase 3Small moleculeCDK4Partial signal
NCT06465368: Percentage of Participants With Complete Cell Cycle Arrest (CCCA) at Day 14 (Day 14): PF-07220060 + Letrozole 88.2% (95% CI 76.6-94.5) vs Letrozole Alone 17.9% (95% CI 10.0-29.8)
BEBT-209Phase 3Small moleculeCDK4 (selective)not yet gradedNo reviewed efficacy summary in this indication
Beruzatatug PelitecanPhase 3Antibody–drug conjugateHER3not yet gradedNo reviewed efficacy summary in this indication
BGB-43395Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
BireociclibPhase 3Small moleculeCDK2/4/6Reliable signal
NCT05077449: BRIGHT-2 (NCT05077449), primary endpoint median PFS: bireociclib (XZP-3287) + fulvestrant 14.7 months vs placebo + fulvestrant 7.3 months; HR 0.54 (95% CI 0.40-0.74); p<0.001
ChidamidePhase 3Small moleculeHDACReliable signal
NCT02482753: Investigator-assessed median PFS: 7.4 months (95% CI 5.5-9.2) chidamide+exemestane vs 3.8 months (95% CI 3.7-5.5) placebo+exemestane; hazard ratio 0.755, p=0.0336
CulmerciclibPhase 3Small moleculeCDK2/CDK4/CDK6, CDK2/4/6/CDK4Partial signal
NCT05375461: Median investigator-assessed PFS: 16.6 months (culmerciclib + fulvestrant) vs 7.5 months (placebo + fulvestrant); HR 0.36 (95% CI 0.26-0.51), P<0.001, meeting the primary endpoint.
DalpiciclibPhase 3Small moleculeCDK4 and CDK6not yet gradedNo reviewed efficacy summary in this indication
Denosumab (Xgeva)Phase 3Monoclonal antibodyRANKLnot yet gradedNo reviewed efficacy summary in this indication
Disitamab VedotinPhase 3Antibody–drug conjugateHER2Partial signal
NCT03052634: Confirmed ORR at 2.0 mg/kg Q2W: 42.9% (9/21) in HER2-overexpression and 33.3% (22/66) in HER2-low advanced breast cancer; median PFS 5.7 and 5.1 months
GiredestrantPhase 3Small moleculeEstrogen receptorPartial signal
NCT04546009: persevERA (NCT04546009), primary endpoint investigator-assessed PFS: giredestrant plus palbociclib median PFS 33.1 months vs letrozole plus palbociclib 28.2 months; HR 0.89 (95% CI 0.76-1.05); p=.1553. missed
HRS-6209Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
HRS-8080Phase 3Small moleculeEstrogen receptor (degrader)not yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
JS105Phase 3Small moleculePI3K-alpha (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication
NTQ1062Phase 3Small moleculeAKT (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
PalazestrantPhase 3Small moleculeEstrogen receptorWeak signalNo reviewed efficacy summary in this indication
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signalNo reviewed efficacy summary in this indication
PembrolizumabPhase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
PrifetrastatPhase 3Small moleculeKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
SaruparibPhase 3Small moleculePARP1 inhibitor (next-gen)not yet gradedNo reviewed efficacy summary in this indication
SHR-6209Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
Sirolimus For Injection (Albumin-Bound)Phase 3Small moleculemTOR (mechanistic target of rapamycin complex 1), via FKBP-12not yet gradedNo reviewed efficacy summary in this indication
TaragarestrantPhase 3Small moleculeEstrogen receptornot yet gradedNo reviewed efficacy summary in this indication
TersolisibPhase 3Small moleculePI3K-alpha (mutant-selective, allosteric)not yet gradedNo reviewed efficacy summary in this indication
Tibremciclib (Kangmeina)Phase 3Small moleculeCDK4 and CDK6Partial signal
NCT05433480: Investigator-assessed PFS: tibremciclib plus fulvestrant median 16.5 months (95% CI 12.8 to 16.6) vs placebo plus fulvestrant 5.6 months (95% CI 4.5 to 9.2); HR 0.37 (95% CI 0.27 to 0.52), P<.001
Trastuzumab PamirtecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
UtidelonePhase 3Small moleculeTubulin / microtubulesnot yet gradedNo reviewed efficacy summary in this indication
Zoledronic AcidPhase 3Small moleculeFarnesyl pyrophosphate synthase (FPPS)not yet gradedNo reviewed efficacy summary in this indication
ZovegalisibPhase 3Small moleculePI3K-alpha (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication
SPH4336Phase 2/3Small moleculeCDK4 and CDK6not yet gradedNo reviewed efficacy summary in this indication
(Z)-EndoxifenPhase 2Small moleculeEstrogen receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication
EvexomostatPhase 2Small moleculeMethionine aminopeptidase 2 (MetAP2, inhibitor)not yet gradedNo reviewed efficacy summary in this indication
HLX43Phase 2Antibody–drug conjugatePD-L1not yet gradedNo reviewed efficacy summary in this indication
Notiretatug RezetecanPhase 2Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
SamuraciclibPhase 2Small moleculeCDK7Partial signalNo reviewed efficacy summary in this indication
ECI830Phase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
GVV858Phase 1/2—CDK2not yet gradedNo reviewed efficacy summary in this indication
IEV407Phase 1——not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 71 furthest-along competitors are listed; 34 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(120 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Faslodex (Fulvestrant) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (9)
November 2026 (1)
Phase 1Metastatic Pancreatic Neuroendocrine TumorRecruiting
Est. primary completion 2026-11 · NCT06663072 · CT.gov ↗
What to watch
December 2026 (8)
Phase 1HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2026-12 · NCT07163481 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12 · NCT06202261 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12 · NCT04115306 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12 · NCT02738866 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12-01 · NCT05305924 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-30 · NCT05870579 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT06239467 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT03006172 · CT.gov ↗
What to watch
2027 (48)
January 2027 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2027-01-31 · NCT02476786 · CT.gov ↗
What to watch
February 2027 (3)
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-02-01 · NCT06447623 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2027-02-26 · NCT06208410 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-02-26 · NCT04524000 · CT.gov ↗
What to watch
March 2027 (2)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-03-01 · NCT06179303 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-03-15 · NCT00585507 · CT.gov ↗
What to watch
April 2027 (10)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04 · NCT07923214 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2027-04 · NCT06736704 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04 · NCT06409390 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04 · NCT07426822 · CT.gov ↗
What to watch
Phase 2/3Advanced/Metastatic CancerActive not recruiting
Est. primary completion 2027-04 · NCT06506955 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-04-01 · NCT05986071 · CT.gov ↗
What to watch
Phase 1/2Breast CancerActive not recruiting
Est. primary completion 2027-04-01 · NCT05319873 · CT.gov ↗
What to watch
Phase 3Breast CancerActive not recruiting
Est. primary completion 2027-04-01 · NCT01953588 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04-10 · NCT07358377 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04-30 · NCT05216432 · CT.gov ↗
What to watch
May 2027 (2)
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-05-05 · NCT06428396 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-05-30 · NCT06784193 · CT.gov ↗
What to watch
June 2027 (5)
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-06 · NCT04920708 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-06 · NCT07117630 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT07557004 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-06-30 · NCT06993844 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-06-30 · NCT07498478 · CT.gov ↗
What to watch
July 2027 (5)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-07 · NCT05735080 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-07-22 · NCT07062965 · CT.gov ↗
What to watch
Phase 1Solid TumorsActive not recruiting
Est. primary completion 2027-07-27 · NCT05238922 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-07-30 · NCT06756932 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-07-31 · NCT07029399 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Low Grade Ovarian Serous AdenocarcinomaActive not recruiting
Est. primary completion 2027-08 · NCT06494150 · CT.gov ↗
What to watch
September 2027 (4)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-09 · NCT07180160 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-09-01 · NCT04985266 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-09-30 · NCT06515470 · CT.gov ↗
What to watch
Phase 2Malignant Neoplasms of Female Genital OrgansActive not recruiting
Est. primary completion 2027-09-30 · NCT03531645 · CT.gov ↗
What to watch
October 2027 (3)
Phase 1HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-10 · NCT06941142 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-10-08 · NCT05090358 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-10-30 · NCT06612814 · CT.gov ↗
What to watch
November 2027 (6)
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-11 · NCT06110793 · CT.gov ↗
What to watch
Phase 2Malignant NeoplasmRecruiting
Est. primary completion 2027-11-04 · NCT06979596 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-11-20 · NCT07333937 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-11-25 · NCT07330544 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-11-30 · NCT05826964 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-11-30 · NCT06764186 · CT.gov ↗
What to watch
December 2027 (6)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12 · NCT05683418 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12 · NCT06555068 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12 · NCT07227233 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05608252 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05601440 · CT.gov ↗
What to watch
Phase 2Breast CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT04567420 · CT.gov ↗
What to watch
2028 (31)
January 2028 (3)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-01 · NCT07235618 · CT.gov ↗
What to watch
Phase 2Breast CancerActive not recruiting
Est. primary completion 2028-01-01 · NCT05328440 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-01-31 · NCT05867251 · CT.gov ↗
What to watch
February 2028 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-02-28 · NCT07287917 · CT.gov ↗
What to watch
March 2028 (2)
Phase 1Advanced/Metastatic Solid TumorsNot yet recruiting
Est. primary completion 2028-03 · NCT07480681 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-03-31 · NCT06788197 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-04-30 · NCT06982521 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2Endometroid Endometrial CancerActive not recruiting
Est. primary completion 2028-05-01 · NCT05154487 · CT.gov ↗
What to watch
June 2028 (2)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-06 · NCT07857226 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-06-30 · NCT07666555 · CT.gov ↗
What to watch
July 2028 (2)
Phase 1Inguinal Hernia Unilateral, Inguinal Hernia Without Obstruction or GangreneRecruiting
Est. primary completion 2028-07 · NCT07604272 · CT.gov ↗
What to watch
Phase 2Salivary Gland Carcinoma, Precision TherapyRecruiting
Est. primary completion 2028-07-10 · NCT06145308 · CT.gov ↗
What to watch
August 2028 (3)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-08 · NCT06998407 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-08-15 · NCT05467891 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2028-08-31 · NCT07038369 · CT.gov ↗
What to watch
September 2028 (3)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-09 · NCT07861932 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-09-25 · NCT06726148 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-09-28 · NCT07619066 · CT.gov ↗
What to watch
October 2028 (2)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-10-31 · NCT07905001 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-10-31 · NCT07368998 · CT.gov ↗
What to watch
November 2028 (4)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-11 · NCT06625775 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorRecruiting
Est. primary completion 2028-11-01 · NCT07226349 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-11-18 · NCT07340619 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-11-30 · NCT07784036 · CT.gov ↗
What to watch
December 2028 (7)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12 · NCT07389733 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-12 · NCT07618390 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-14 · NCT06997029 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-14 · NCT04646759 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-30 · NCT07109726 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT05816655 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT05524584 · CT.gov ↗
What to watch
2029 (17)
January 2029 (1)
Phase 1/2Locally Advanced Solid TumorNot yet recruiting
Est. primary completion 2029-01 · NCT07944092 · CT.gov ↗
What to watch
March 2029 (3)
Phase 1Patients With Advanced Solid TumorsNot yet recruiting
Est. primary completion 2029-03 · NCT07787520 · CT.gov ↗
What to watch
Phase 1/2Advanced Cancer, Metastatic CancerRecruiting
Est. primary completion 2029-03-31 · NCT05394103 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-03-31 · NCT06757634 · CT.gov ↗
What to watch
April 2029 (2)
Phase 4HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-04 · NCT05362760 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-04-14 · NCT07318805 · CT.gov ↗
What to watch
May 2029 (2)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-05 · NCT07558733 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-05-31 · NCT07207070 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-06-15 · NCT07748208 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-08-27 · NCT04606446 · CT.gov ↗
What to watch
October 2029 (2)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-10-07 · NCT04557449 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2029-10-28 · NCT07767474 · CT.gov ↗
What to watch
November 2029 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2029-11 · NCT07937605 · CT.gov ↗
What to watch
December 2029 (4)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-12 · NCT06120283 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-12-18 · NCT06380751 · CT.gov ↗
What to watch
Phase 1CancerRecruiting
Est. primary completion 2029-12-31 · NCT07540572 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2029-12-31 · NCT05226871 · CT.gov ↗
What to watch
2030 (10)
March 2030 (1)
Phase 1HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2030-03-22 · NCT07897721 · CT.gov ↗
What to watch
June 2030 (1)
Phase 4HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2030-06-28 · NCT05161195 · CT.gov ↗
What to watch
July 2030 (2)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-07 · NCT05768139 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-07-01 · NCT05564377 · CT.gov ↗
What to watch
August 2030 (2)
Phase 1HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2030-08-15 · NCT07867262 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2030-08-31 · NCT07716046 · CT.gov ↗
What to watch
September 2030 (2)
Phase 1/2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2030-09-01 · NCT07811232 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗
What to watch
October 2030 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-10 · NCT05933395 · CT.gov ↗
What to watch
December 2030 (1)
Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2030-12-31 · NCT07892274 · CT.gov ↗
What to watch
2031 (2)
May 2031 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2031-05-09 · NCT07288359 · CT.gov ↗
What to watch
June 2031 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2031-06-30 · NCT06849947 · CT.gov ↗
What to watch
2032 (2)
March 2032 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2032-03-23 · NCT07679269 · CT.gov ↗
What to watch
June 2032 (1)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2032-06-08 · NCT07604571 · CT.gov ↗
What to watch
2034 (1)
October 2034 (1)
Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2034-10-30 · NCT07802626 · CT.gov ↗
What to watch

See the full readout calendar ↗